Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Intellia’s CRISPR-based therapy maintained reductions in the levels of a misfolded protein in the nerves of patients with a rare disease called transthyretin amyloidosis. Functional improvement was also seen in the patients. The data come ...